The Cystic Fibrosis Foundation and clinical trials in organ transplantation (CTOT) investigators aim to facilitate access to well-characterized specimens and clinical data collected and banked through the CTOT-20 and CTOT-Extension (CTOT-ES) studies. This unique resource is being made available to meritorious research proposals from the broader lung transplant community. Research projects may address the endotyping and mechanistic understanding of chronic lung allograft dysfunction (CLAD), identification and validation of biomarkers for early detection and monitoring of CLAD, and discovery of potential therapeutic targets to prevent or treat CLAD. If planning a study that only uses CTOT data, applicants are welcomed to propose investigation of lung transplant outcomes other than CLAD. In either case, the applicant will be required to partner with a CTOT investigator.
Please note: This is a one-time request for applications (RFA) with a letter of intent (LOI). Full applications will be solicited by invitation only after review of a LOI.
United States residents and applicants from outside the United States are welcome to apply. Funding varies based on the type of proposal:
- Hypothesis-generating or data-only research: Funding of up to $50,000 per year for up to two years, plus 12% indirect costs may be requested.
- Hypothesis-based research using both specimens and data: Funding of up to $100,000 per year for up to two years, plus 12% indirect costs may be requested.
Industry-sponsored research projects are not eligible to apply through this program and instead should consider applying to the Therapeutics Development Awards program. For additional information, please contact email@example.com.
Areas of Interest
The goal of this RFA is to identify highly relevant projects that aim to use available CTOT specimens and/or data in new ways to improve knowledge of CLAD pathogenesis and explore new approaches to detection, prevention, monitoring, or treatment of CLAD. Areas of interest include, but are not limited to the following:
- Improving the understanding of CLAD endotypes, particularly defining mechanisms underlying the development of obstructive, restrictive, or mixed CLAD
- Defining pathogenesis of CLAD with the goal of identifying new therapeutic targets
- Identifying and/or validating physiologic techniques or biomarkers for early diagnosis and/or monitoring of CLAD
- Applying advances in lung transplant immunology and mechanisms of fibrosis to the identification and/or validation of biomarkers and therapeutic approaches to prevent or treat CLAD
- Identifying differences in relevant transplant outcomes, including acute rejection, infections, renal dysfunction, malignancies, and CLAD in CF lung transplant recipients
If planning a study that only uses CTOT data, applicants are welcomed to propose investigating lung transplant outcomes other than CLAD. Projects may combine the use of CTOT data with available specimens collected through other efforts.
A goal of this RFA is to promote collaboration between applicants and CTOT investigators. See Policies and Guidelines for more information.
Policies and Guidelines
Please review the 2022 Policies and Guidelines for complete submission information.
All letters of intent and full applications for 2022 must be submitted online at awards.cff.org by 5 p.m. ET.
Letter of Intent: April 20, 2022
Full application: August 23, 2022
For More Information
For more information regarding the priorities of this program, please contact firstname.lastname@example.org.
Those who are interested in any funding programs offered by the Foundation may get further information or discuss the potential relevance of their studies or research by contacting the Grants and Contracts Office at email@example.com.
Please Direct Inquiries to:
Grants and Contracts Office
Cystic Fibrosis Foundation
4550 Montgomery Ave.
Suite 1100 N
Bethesda, MD 20814